论文部分内容阅读
目的:评价前列地尔脂微球载体制剂治疗急性缺血性卒中的疗效及安全性。方法:发病1周内的76例急性脑梗死患者随机分为试验组和对照组,每组各38例。试验组接受前列地尔脂微球载体制剂治疗,对照组接受低分子右旋糖苷加丹参注射液治疗。疗程14 d。主要疗效评价指标为d 21的躯体日常生活活动能力Barthel指数(BI),BI>95分定义为良好预后。次要疗效评价指标为d 21欧洲卒中神经功能评分(ESS)。安全性评价指标为血小板聚集率、凝血时间、纤维蛋白原、D-Dimer、血脂和不良反应。结果:试验组和对照组预后良好率分别为26.3%与2.6%(P=0.007)。试验组和对照组ESS改善的总有效率为47.37%与21.05%(P=0.016)。治疗期间血小板聚集功能下降明显,试验组比对照组下降明显(P<0.05)。试验组与对照组不良反应发生率分别为7.89%与5.26%(P>0.05)。结论:前列地尔脂微球载体制剂治疗急性脑梗死安全性好,有一定疗效。
Objective: To evaluate the efficacy and safety of alprostadil liposome-loaded microsphere preparation in the treatment of acute ischemic stroke. Methods: A total of 76 patients with acute cerebral infarction within one week after onset were randomly divided into experimental group and control group, with 38 cases in each group. The experimental group received alprostadil lipid microspheres carrier preparation treatment, the control group received low molecular weight dextran plus Salvia injection. Treatment 14 d. The main efficacy evaluation index of Bartlett index (BI), BI> 95 was defined as good prognosis. The secondary outcome measure was d 21 European Stroke Nerve Function Score (ESS). Safety evaluation indicators for platelet aggregation rate, clotting time, fibrinogen, D-Dimer, lipids and adverse reactions. Results: The good prognosis of experimental group and control group were 26.3% and 2.6% respectively (P = 0.007). The total effective rate of improvement of ESS in experimental group and control group was 47.37% and 21.05% (P = 0.016). Platelet aggregation decreased significantly during treatment, the experimental group decreased significantly compared with the control group (P <0.05). The incidences of adverse reactions in the experimental and control groups were 7.89% and 5.26%, respectively (P> 0.05). Conclusion: Alprostadil lipid microsphere carrier preparation is safe and effective in treating acute cerebral infarction.